Physician profile
Audrey Ryan
NPI 1154052777
$2,917.59
in general payments reported to CMS, 2019-2025
28 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.66 · 2024: $1,334 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.85 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $318.70 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $215.47 | 2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $211.61 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.03 | 2024-2025 | Xifaxan |
| Alk-Abello, INC | $170.42 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Abbvie INC. | $155.30 | 2024-2025 | |
| Exact Sciences Corporation | $142.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $136.45 | 2024-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $101.45 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $95.61 | 2023-2025 | Symbravo, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.15 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $84.38 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $71.27 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $68.06 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.00 | 2024-2025 | Caplyta |
| Insulet Corporation | $48.94 | 2025 | Omnipod |
| Amgen INC. | $40.36 | 2024 | Repatha, Otezla |
| Ferring Pharmaceuticals INC. | $39.28 | 2024 | Rebyota |
| Lundbeck LLC | $37.07 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $33.84 | 2025 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $25.02 | 2024 | Aptima |
| Grifols USA, LLC | $22.93 | 2024 | Prolastin-C Liquid |
| Edwards Lifesciences Corporation | $20.66 | 2024 | Sapien 3 Ultra Resilia |
| Kaleo, INC. | $20.51 | 2024 | Auvi-Q |
| E.R. Squibb & Sons, L.L.C. | $19.57 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $18.05 | 2024 | Trintellix |
| Aimmune Therapeutics, INC. | $16.12 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.